2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes
To investigate the impact of the 2017 revisions of McDonald criteria on the diagnosis of multiple sclerosis (MS) in a cohort of patients with clinically isolated syndrome (CIS) and dissemination in space (DIS) of demyelinating lesions.
We retrospectively analyzed 137 patients with CIS + DIS from two Italian MS centers.
Application of the 2017 revisions of McDonald criteria in our cohort led to a diagnosis of MS in 82.5% of the patients who could have not been diagnosed with MS according to the previous criteria at the time of the first demyelinating event. After a follow-up of 3.8 ± 2.9 years, 85.8% of these patients eventually satisfied also the previous (2010) criteria.
Application of the 2017 revisions of McDonald criteria results in an earlier diagnosis of MS in a large percentage of CIS patients destined to convert to MS.
KeywordsClinically isolated syndrome Multiple sclerosis Conversion Diagnostic criteria Dissemination in space Dissemination in time Symptomatic gadolinium enhancing lesion Oligoclonal bands
Compliance with ethical standards
Conflicts of interest
LG received travel grants from Biogen, Novartis, Teva, Sanofi Genzyme and Almirall to attend national and international conferences. LP has received research grant from Associazione Italiana Sclerosi Multipla (AISM) and Genzyme; consulting and/or lecture fees and travel grants from Biogen, Genzyme, Novartis and Teva. AM received travel grants from Teva and Sanofi Genzyme to attend national conferences. CP has received consulting and/or lecture fees and/or research funding and travel grant from Almirall, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva. PC received/receive research support from Bayer Schering, Biogen-Dompé, Boehringer Ingelheim, Eisai, Lundbeck, Merck-Serono, Novartis, Sanofi-Aventis, Sigma-Tau, and UCB Pharma. MDF participated to advisory boards and received speaker/writing honoraria and funding for traveling from: Bayer, Biogen Idec, Genzyme, Merck, Novartis, Roche and Teva. PE, PS, MCC report no conflicts of interests.
- 9.McNicholas N, Lockhart A, Yap SM et al (2018) New versus old: implications of evolving diagnostic criteria for relapsing–remitting multiple sclerosis. Mult Scler 21:1352458518770088Google Scholar
- 10.Beesley R, Anderson V, Harding KE et al (2018) Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis. Mult Scler 1:1352458518778007Google Scholar
- 11.Filippi M, Preziosa P, Meani A et al (2017) Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol 4422:1–10Google Scholar